A study
involving 2408 donors (18–60 years) indicated that bone pain (primarily
back and hips) as a result of filgrastim treatment is observed in 80% of
donors by day 4 post-injection. This pain responded to acetaminophen or
ibuprofen in 65% of donors and was characterized as mild to moderate in
80% of donors and severe in 10%. Bone pain receded post-donation to 26%
of patients 2 days post-donation, 6% of patients one week
post-donation, and <2% 1 year post-donation. Donation is not
recommended for those with a history of back pain. Other symptoms
observed in more than 40% of donors include myalgia, headache, fatigue,
and insomnia. These symptoms all returned to baseline 1 month
post-donation, except for some cases of persistent fatigue in 3% of
donors. In one metastudy that
incorporated data from 377 donors, 44% of patients reported having
adverse side effects after peripheral blood HSCT. Side effects included
pain prior to the collection procedure as a result of GCSF injections,
post-procedural generalized skeletal pain, fatigue and reduced energy.
A study
involving 2408 donors (18–60 years) indicated that bone pain (primarily
back and hips) as a result of filgrastim treatment is observed in 80% of
donors by day 4 post-injection. This pain responded to acetaminophen or
ibuprofen in 65% of donors and was characterized as mild to moderate in
80% of donors and severe in 10%. Bone pain receded post-donation to 26%
of patients 2 days post-donation, 6% of patients one week
post-donation, and <2% 1 year post-donation. Donation is not
recommended for those with a history of back pain. Other symptoms
observed in more than 40% of donors include myalgia, headache, fatigue,
and insomnia. These symptoms all returned to baseline 1 month
post-donation, except for some cases of persistent fatigue in 3% of
donors. In one metastudy that
incorporated data from 377 donors, 44% of patients reported having
adverse side effects after peripheral blood HSCT. Side effects included
pain prior to the collection procedure as a result of GCSF injections,
post-procedural generalized skeletal pain, fatigue and reduced energy.
No comments:
Post a Comment